Our previous study of single dose artemisinin-naphthoquine (ANT) in adult majority male patients showed it as a safe, tolerable, and very effective treatment for uncomplicated malaria. More data is required to verify safety and efficacy from other age groups before this new drug could be widely used in Primary Health Care (PHC)s in Indonesia. For this study, we modified the 2009 WHO guidelin…
A practical and simple Artemisinin based combination therapy (ACT) with good compliance in adult patients for all malaria species has been shown in the first article: “Efficacy and Safety of Artemisininnaphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia”. It is worth to add data safety and efficacy of …
Indonesia as a malaria endemic country is recommended to use Artemisinin-based Combination Therapy (ACT) for P. vivax malaria. Confirmation of Chloroquine resistant and ACT efficacy for P. vivax need to be investigated for supporting malaria treatment policy. Papua and East Nusa Tenggara (NTT) contribute the main malaria cases in Indonesia. To evaluate efficacy and safety of A…
This study is part of the study with title "Monitoring drug resistance in subjects with P. falciparum and P.vivax malaria in Kalimantan and Sulawesi, Indonesia" which the objective to assess the efficacy and safety of Dihydroartemisinin - Piperaquine (DHP) in patients with malaria vivax in Kalimantan and Sulawesi. The design of study was a cross-sectional study and prospective evaluation of 87 …
Malaria is still a public health problem in Indonesia. The clinical manifestation of malaria is varied, and many factors may influence its clinical manifestation. Despite the species of malaria, density of parasitemia is known related to the severity or malignancy of malaria. It is worth to analyse the clinical and laboratory data of malaria cases in monitoring dihydroartemisinin-piperaquine (D…
Since 2008, Dihydroartemisinin-Piperaquine (DHP) has been used as the first-line drug for treatment of falciparum malaria in Papua, which gradually will also be used in other endemic areas. The objective of the study was to determine the safety and efficacy of DHP. Patients with uncomplicated malaria due to Plasmodium falciparum were enrolled and treated with supervised DHP (arterakin ®, no. …
Background: Clinical and parasitological response of malaria treatment on day 3 follow-up (D3) is a crucial condition to predict the successful of treatment. D3 is a period time that Early Treatment Failure may happen which may cause severe or complicated malaria. Moreover, if the asexual parasitemia is still detected more than 10% study subjects, it is assumed parasites resistance against arte…